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Highlights: 
 Intranasal oxytocin reduces salivary cortisol in anorexia nervosa 
 Intranasal oxytocin reduced attentional bias towards food images following a 
standard smoothie challenge 
 There was no effect of intranasal oxytocin on smoothie intake in a standard 
smoothie challenge in among people with anorexia nervosa or healthy 
comparison individuals 
 
Abstract 
Background: Anorexia nervosa (AN) is characterised by severe malnutrition as well as 
intense fear and anxiety around food and eating with associated anomalies in 
information processing. Previous studies have found that the neuropeptide, 
oxytocin, can influence eating behaviour, lower the neurobiological stress response 
and anxiety among clinical populations, and alter attentional processing of food and 
eating related images in AN.  
 
Methodology: Thirty adult women with AN and twenty-nine healthy comparison 
(HC) women took part in the current study. The study used double blind, placebo 
controlled, crossover design to investigate the effects of a single dose of intranasal 
oxytocin (40 IU) on a standard laboratory smoothie challenge, and on salivary 
cortisol, anxiety, and attentional bias towards food images before and after the 
smoothie challenge in AN and HC participants. Attentional bias was assessed using a 
visual probe task. 
 
 3 
Results: Relative to placebo intranasal oxytocin reduced salivary cortisol and altered 
anomalies in attentional bias towards food images in the AN group only. The 
oxytocin-induced reduction in attentional avoidance of food images correlated with 
oxytocin induced reduction in salivary cortisol in the AN group before the smoothie 
challenge. Intranasal oxytocin did not significantly alter subjective feelings of anxiety 
or intake during the smoothie challenge in the AN or HC groups.   
  
Conclusions: Intranasal oxytocin may moderate the automated information 
processing biases in AN and reduce neurobiological stress. Further investigation of 
the effects of repeated administration of oxytocin on these processes as well as on 
eating behaviour and subjective anxiety would be of interest.  
 
Introduction 
 
Anorexia nervosa (AN) is characterised by an intense fear of food and eating with 
associated avoidance behaviours and severe malnourishment (American Psychiatric 
Association, 2013). Over time these associations become stronger and cues related 
to food and eating become linked to changes in brain function and information 
processing biases begin to develop (Schmidt and Treasure, 2006; Treasure et al., 
2012; Yackobovitch-Gavan et al., 2009). To date, a number of studies have 
demonstrated that relative to healthy individuals, people with AN have elevated 
plasma and salivary cortisol levels, which suggests a dysregulation of the 
hypothalamic-pituitary-adrenal (HPA) axis (Bailer and Kaye, 2003; Connan et al., 
2003; Lawson et al., 2013b; Licinio et al., 1996). Furthermore, behavioural studies 
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have found that people with AN have elevated autonomic responses to illness-
related stimuli, such as food (Léonard et al., 1998; Rigaud et al., 2007; Soussignan et 
al., 2011; Uher et al., 2004). A study investigating the effect of a blind gastric load of 
0, 300, or 700 calories on endocrine responses in AN found that the cortisol response 
increased with the calorie content of the gastric load in the AN participants (Rigaud 
et al., 2007). Further work has also demonstrated that relative to healthy 
participants, people with AN report greater fear and disgust in response to food 
stimuli, and have elevated corrugator facial EMG (i.e. frowning) and physiological 
arousal response to food images and when confronted with a test meal (Léonard et 
al., 1998; Soussignan et al., 2011; Uher et al., 2004).  
 
In addition to elevated anxiety and stress around eating, people with AN also have 
anomalies in attention towards food (Brooks et al., 2011). A meta-analysis found that 
people with AN show an increased attentional bias (AB) towards food images 
(Brooks et al., 2011). Another study utilising eye-tracking methodology found that 
relative to healthy participants, people with AN showed early AB towards food 
images, but later avoidance of food images (Giel et al., 2011). Similarly, 
electroencephalogram (EEG) and magnetoencephalography (MEG) studies have 
found elevated early and reduced later posterior activation in people with AN 
compared to healthy individuals in response to food stimuli (Godier et al., 2016; 
Wolz et al., 2015). Interestingly, a study by Cardi et al. (2013) investigated AB 
towards food images before and after a standard test meal challenge and found that 
inpatients with AN showed greater AB towards food images following exposure to a 
test meal challenge. Thus, taken together, these findings suggest that anomalies in 
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AB towards food images is a prominent feature of AN and is likely fuelled by stress 
and anxiety around food and eating. 
 
Animal studies have demonstrated that the neuropeptide oxytocin is involved in 
many regulatory functions in the central nervous system including stress response 
and food intake (Cochran et al., 2013; Olszewski et al., 2010).  A recent meta-analysis 
found that intranasal oxytocin significantly reduced cortisol response to stressful 
stimuli among clinical populations of people suffering from a range of disorders, 
including depression, substance dependence, fragile X syndrome and borderline 
personality disorder, characterised by a chronic dysregulated and hyperactivated 
HPA axis (Cardoso et al., 2014). Additionally, emerging evidence from animal studies 
has demonstrated that central administration of an oxytocin receptor agonist can 
normalise novelty-induced decrease in food intake in mice, suggesting that oxytocin 
may play a role in moderating the influence of stress and anxiety on eating 
(Olszewski et al., 2014). Thus intranasal oxytocin may be helpful facilitating exposure 
treatment for food restriction fuelled by anxiety.   
 
There has been increasing interest in the possibility that oxytocin may be involved in 
the pathophysiology of eating disorders (Maguire et al., 2013). A recent meta-
analysis reported that peripheral and cerebrospinal fluid (CSF) levels of endogenous 
oxytocin were significantly lower in AN relative to normal weight controls, which the 
authors suggested is likely associated with dysregulation of the HPA axis (Rutigliano 
et al., 2016). Additionally, another study has reported atypical, elevated oxytocin 
response to food intake in AN, which was associated with pre-meal hypoactivation of 
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the hypothalamus, orbitofrontal cortex, insula, and amygdala in response to food 
images in AN relative to healthy participants (Lawson et al., 2013b; Lawson et al., 
2012). Moreover, a recent proof of concept study found that a single dose of 40IU of 
intranasal oxytocin reduced anomalies in AB towards images of food, eating, and 
negative body shape in people with AN (Kim et al., 2014a). The authors also found 
that intranasal oxytocin led to a reduction in caloric intake in the 24 hours following 
administration in participants with bulimia nervosa (Kim et al., 2015). These findings 
suggest that intranasal oxytocin can alter anomalies in attentional processes to 
specific and general aversive stimuli in AN and may alter eating behaviour.  
 
The aim of the current study was to examine the impact of a single dose of intranasal 
oxytocin on a standard smoothie challenge, as well as neurobiological stress and AB 
towards food images, as measured with a visual probe task, before and after the 
smoothie challenge in adult women with AN and gender and age matched healthy 
control (HC) participants. Based on previous findings outlined above, we 
hypothesised that relative to HCs, participants with AN would consume less during 
the smoothie challenge, have elevated anxiety and salivary cortisol, and anomalies in 
AB towards food images before and after the smoothie challenge. Additionally, we 
hypothesised that oxytocin administration would decrease anxiety, increase 
smoothie intake, reduce cortisol and alter anomalies in AB towards food images in 
participants with AN. 
 
Methods and Materials 
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Participants 
Fifty-nine women participated in the study. Thirty women met the DSM-5 criteria for 
AN, with mean BMI of 16.30 (SD = 2.04) and age of 26.20 (SD = 6.82). Diagnosis was 
confirmed using the Structured Clinical Interview for DSM-5 (First, 2015). Fifteen of 
the AN participants were recruited from the South London and Maudsley NHS 
Foundation Trust inpatient unit and were in treatment. The other fifteen AN 
participants were recruited through ED charities (BEAT, Succeed). Fifteen of the AN 
participants were taking medication (anti-depressants) during the study. 
 
The HC participants (N = 29), with mean BMI of 23.25 (SD = 3.65) and age of 26.83 
(SD = 8.54), were recruited from the community and amongst King’s College London 
students and staff. HC participants were of normal weight and were screened for 
current or past psychiatric disorders, and alcohol or drug misuse with the Structured 
Clinical Interview for DSM-5 (First, 2015). Participants were excluded from the study 
if they reported medical or psychiatric problems, a history of or current alcohol or 
drug abuse, current impairments in cardiovascular functioning, pregnancy or plans to 
become pregnant during the study. Prior to participating in the study, all participants 
gave a written informed consent. Ethical approval for the study was obtained from 
National Research Ethics Service (NRES) committee (14/LO/0128) and all procedures 
were conducted in accordance with the latest declaration of Helsinki (2008).  
 
The sample size was based on power analysis conducted with G*Power for a 
repeated measures design (Faul et al., 2007). To ensure adequate power (0.80) to 
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detect an effect in the mixed model, the total recommended sample size was 60 
participants. 
 
Experimental design 
The study employed a double blind, placebo controlled, within subjects, crossover 
design. All participants received a single dose of both oxytocin and placebo in 
separate sessions. The treatment order was pseudo-randomised so that half of the 
AN participants and half of the HC participants received oxytocin in the first session 
and the other half of the AN and HC participants received oxytocin in the second 
session. Only the Maudsley pharmacy, responsible for dispensing the compounds 
were aware of the order in which each participant received the compounds. The 
experimenter and the participants were both blind to treatment order.  
 
The study flow chart is presented in Supplementary Figure 1. Prior to administration 
of the compounds participants were asked to provide a saliva sample for cortisol 
analysis, and to provide a baseline rating of anxiety on a visual analogue scale (VAS) 
(for further details see Supplementary information). The intranasal oxytocin and the 
placebo were self-administered by the participants in ten sprays, five sprays in each 
nostril every 45 seconds (for further details see Supplementary information). Fifty 
minutes after administration, participants gave the second saliva sample and VAS 
anxiety rating. The first visual probe task was then administered approximately 55 
minutes after administration of the compound (T1; for further details see 
Supplementary information). This was followed by the smoothie challenge consisting 
of a 250 ml fruit smoothie (a choice from 3 Innocent smoothie flavours: strawberries 
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and bananas, mangoes and passion fruits, and kiwis, apples and limes). All labels 
were kept on the bottles and this contained the calorie content and nutritional 
information. The participants were encouraged to consume as much of the smoothie 
as they liked under non-supervised conditions and were left for 15 minutes to do 
this. If participants refused to have a smoothie they were informed that they did not 
have to have it, but were encouraged to try it and left with the smoothie for the 
duration of the challenge. Following this, participants gave a third VAS anxiety rating 
and the second visual probe task was administered, approximately 75 minutes after 
administration of the compound (T2; for further details see Supplementary 
information). Finally, the third saliva sample was collected approximately 80 minutes 
after administration. The timing was based on previous work investigating the 
effects of intranasal oxytocin on AB in eating disorders and on cerebral blood flow 
among healthy individuals (Kim et al., 2014a; Paloyelis et al., 2016).  
 
The two sessions were scheduled a minimum of one day and maximum of five days 
apart. All HC and AN participants who were menstruating regularly during the study 
were tested during the follicular phase, 1-15 days following the onset of a menstrual 
cycle.  All participants were asked to refrain from consuming any alcoholic or 
caffeinated beverages twelve hours prior to the sessions. Additionally, the 
participants were asked to not consume any food two hours prior to the sessions, in 
order to minimise effects of fullness and hunger on the tasks. 
 
 
 
 10 
Visual probe task 
A visual probe detection task was used to investigate AB towards and away from 
food and neutral, non-food images in AN. The task was amended from that used in a 
previous study (Cardi et al., 2013), and the food images were acquired from a 
standardised set of images and depicted a variety of savoury and sweet food items 
on a blue background (Uher et al., 2004). The food images depicted highly palatable 
food, and were matched for size and calorie content. The non-food images consisted 
of neutral images of furniture. In the visual probe detection task participants were 
presented with two images simultaneously on a computer screen side by side for 
500ms. One of the images then revealed one of two visual probes underneath them 
and participants were instructed to press specific keys on the keyboard to indicate 
which probe they saw. The probe was presented until participants responded. The 
task was presented with E-prime software (Psychology Software Tools, Sharpsburg, 
USA) and consisted of 96 trials. The task lasted approximately 3 minutes. Further 
details regarding the visual probe task are presented in Supplementary information.  
 
Statistical analysis 
All data was analysed using Stata 14 (StataCorp, 2015) and p < 0.05 was considered 
significant. The self-report questionnaire data were analysed with non-parametric 
two-sample median Chi2 tests.  Effect sizes were estimated with Cramer’s ϕ, which 
can be interpreted as small (0.10), medium (0.30), or large (0.50) (Cohen, 1988). 
 
Due to the highly skewed nature of the smoothie data, logarithm 10 transformation 
was performed prior to analysis. Group differences in smoothie intake in millilitres 
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(ml) consumed as well as the effect of oxytocin/placebo on consumption were then 
analysed with a bootstrapped mixed linear model with 1000 repetitions using the 
bootstrap and mixed functions in Stata (StataCorp, 2015). Significant interactions 
were further investigated by computing post-hoc contrasts and pairwise 
comparisons. 
 
The AB data was analysed separately for the 500ms and 1250ms ITI blocks with a 
2x2x2 mixed linear model using the mixed function with bootstrapping (1000 
repetitions) in Stata 14 (StataCorp, 2015). Drug (oxytocin, placebo), time (before 
smoothie challenge, after smoothie challenge), and group (AN, HC) were entered as 
fixed effects with a random intercept and random slope on drug. Similarly, the VAS 
anxiety and salivary cortisol data were analysed with a 2x3x2 bootstrapped mixed 
model with drug (oxytocin, placebo), time (baseline, before smoothie challenge, 
after smoothie challenge), and group (AN, HC) and a random intercept and random 
slope on drug. Significant interactions were explored further by calculating contrasts 
and pairwise post-hoc comparisons using the contrast and pwcompare functions 
(StataCorp, 2015).  
 
We additionally explored whether oxytocin induced changes in AB scores correlated 
with oxytocin induced changes in VAS anxiety ratings and salivary cortisol before and 
after the smoothie challenge within the AN group. AB delta scores were calculated 
by first adding a constant to all AB data to ensure no AB scores were negative. The 
AB scores from the placebo session were then subtracted from the AB scores from 
the oxytocin session. Thus, negative scores indicated greater AB towards food 
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images in the placebo session and positive scores indicated greater AB towards food 
images in the oxytocin session. VAS anxiety and salivary cortisol delta scores were 
calculated in a similar manner. We then conducted correlation analyses to 
investigate significant correlations between the deltas in Stata using the spearman 
function (StataCorp, 2015).   
 
Effects of medication status on AB, salivary cortisol, and VAS anxiety ratings as well 
as on the effects of oxytocin are presented in Supplementary information. 
 
Results 
 
Demographic and clinical characteristics 
The clinical and self-report questionnaire data is presented in Table 1 and was 
corrected for multiple comparisons with the false discovery rate set at q < 0.05 
(Benjamini and Hochberg, 1995). Following correction, p < 0.04 was considered 
significant. The AN and HC groups were matched for age, and as expected the AN 
group had lower BMI than the HC group. The AN group also scored higher on the 
EDEQ reporting higher levels of restraint, eating concern, weight concern, and shape 
concern compared to the HC group. Additionally, the AN group scored higher on the 
DASS reporting elevated levels of depression, anxiety, and stress relative to the HC 
group.  
 
Table 1. Clinical and demographic sample characteristics 
---------------------------------------------------TABLE 1--------------------------------------------------- 
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Smoothie intake  
Smoothie intake in the oxytocin and placebo conditions are summarised separately 
for each group in Table 2 (see Supplementary Figure 2 for visual presentation). The 
mixed model revealed a significant effect of Group, with HC participants consuming 
significantly more smoothie during the challenge than AN participants across 
conditions. There was no significant effect of Drug  or Drug x Group interaction. 
Eleven AN participants did not consume any of the smoothie in the placebo 
condition, and nine of these eleven AN participants also did not consume any 
smoothie in the oxytocin condition.   
 
Table 2. Smoothie intake in millilitres (ml) in the AN and HC groups in the oxytocin 
and placebo conditions. 
----------------------------------------------------TABLE 2-------------------------------------------------- 
 
 
 
AB: 500ms ITI blocks 
The AB scores in the 500ms ITI blocks among the AN and HC groups following 
oxytocin and placebo administration are presented in Table 3 (see Supplementary 
Figure 3A,B for visual presentation). P-values were corrected for multiple 
comparisons with the false discovery rate set at q < 0.05 (Benjamini and Hochberg, 
1995). Following correction, p < 0.02 was considered significant.  
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The mixed model revealed a significant Drug x Time x Group interactions (Table 3). 
The 3-way interaction was further investigated in three ways. First we explored the 
Drug x Time interaction separately within the AN and HC groups. The results 
revealed that the Drug x Time interaction was significant within the AN group (Χ2 = 
7.78, p = 0.005), but not within the HC group (Χ2 = 0.94, p = 0.333). The interaction 
was then further investigated within the AN group by exploring the effects of Drug at 
T1 and T2. The results revealed that oxytocin administration significantly reduced AB 
towards food images in the AN group at T2, after the smoothie challenge, (Z = -2.72, 
p = 0.007, 95% CI [-41.78, -6.78]), but not at T1, before the smoothie challenge al, (Z 
= 1.38, p = 0.168, 95% CI [-4.66, 26.72]). 
 
Finally, we explored the Group x Time interaction separately in the oxytocin and 
placebo conditions.  The results revealed a significant Group x Time interaction only 
in the placebo condition (Χ2 = 10.03, p = 0.002), but not in the oxytocin condition (Χ2 
= 0.38, p = 0.540). When group differences were explored further, the results 
revealed that AN participants showed significantly more AB away from food images 
than HC participants at T1, before the smoothie challenge, (Z = -3.08, p = 0.002, 95% 
CI [-45.09, -10.02]), but not at T2, after the smoothie challenge, (Z = 1.56, p = 0.118, 
95% CI [-3.46, 30.71]).  
 
We then explored the Group x Drug interaction separately at T1 and T2, which 
revealed no significant interaction at T1, before the smoothie challenge (Χ2 = 3.06, p 
= 0.080), or at T2, after the smoothie challenge (Χ2 = 4.13, p = 0.042).  
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Table 3. AB towards food images before and after the test meal in the AN and HC 
groups. 
---------------------------------------------------TABLE 3--------------------------------------------------- 
 
 
AB: 1250ms ITI blocks 
The attentional bias scores in the 1250ms ITI blocks among the AN and HC groups 
following oxytocin and placebo administration are presented in Supplementary 
Figure 4A,B. The drug x time x group mixed model revealed no significant effects or 
interactions in the 1250ms ITI blocks (Supplementary Table 1).  
 
Salivary cortisol 
Mean salivary cortisol levels are presented separately for each group in the oxytocin 
and placebo conditions in Table 4 (see Supplementary Figure 5 for visual 
presentation). The mixed model revealed a significant effect of Group, with AN 
participants having significantly higher cortisol levels than HC participants across 
conditions and time points (Table 4).  
 
The mixed model additionally revealed a significant Drug x Group interaction. The 
interaction was further explored by exploring the effect of Drug on salivary cortisol 
separately in each group. The results revealed a significant effect of Drug in the AN 
group (Z = -1.99, p = 0.046, 95% CI [-1.30, -0.01]), with AN participants having lower 
salivary cortisol levels in the oxytocin condition. There was no significant difference 
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between oxytocin and placebo in the HC group (Z = 1.94, p = 0.052, 95% CI [-0.004, 
0.84]).  
 
Table 4. Salivary cortisol at each time point in the AN and HC groups 
---------------------------------------------------TABLE 4--------------------------------------------------- 
 
 
 
Self-reported VAS anxiety ratings 
Mean VAS anxiety ratings are presented separately for each group in the oxytocin 
and placebo conditions in Supplementary Figure 6. The mixed model exploring group 
differences in anxiety ratings at different time points in the oxytocin and placebo 
conditions revealed a significant effect of Time (Supplementary Table 2). VAS anxiety 
ratings were significantly higher after the smoothie challenge than before the 
smoothie challenge across groups (Z = 3.62, p < 0.001, 95% CI [0.03, 0.09]). There 
were no significant differences in self-reported anxiety at baseline and before the 
smoothie challenge (Z = -1.85, p = 0.064, 95% CI [-0.07, 0.002]) or at baseline and 
after the smoothie challenge (Z = 1.21, p = 0.224, 95% CI [-0.01, 0.06]).  
 
Correlations between oxytocin-induced changes in AB, anxiety, and salivary cortisol: 
The correlational analysis revealed a significant inverse correlation between salivary 
cortisol delta scores and oxytocin-induced changes in AB before the smoothie 
challenge (ρ = -0.41, p = 0.026). Inverse correlation between VAS anxiety delta scores 
and oxytocin induced changes in AB before the smoothie challenge also approached 
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significance (ρ = -0.31, p = 0.097). There were no significant correlations between 
oxytocin-induced changes in AB and cortisol delta scores (ρ = -0.11, p = 0.574), 
anxiety delta scores (ρ = -0.08, p = 0.692) after the smoothie challenge, or BMI 
(before smoothie challenge: ρ = 0.09, p = 0.631, after smoothie challenge: ρ = 0.06, p 
= 0.752).   
 
Discussion 
The aim of the current study was to examine the effects of a single dose of intranasal 
oxytocin on smoothie intake during a standard smoothie challenge as well as on 
salivary cortisol and AB towards food images before and after the smoothie 
challenge. As hypothesised, relative to HCs, the majority of the AN participants 
consumed less smoothie during the smoothie challenge and had elevated anxiety 
and salivary cortisol levels, and showed anomalies in AB towards food images. 
Contrary to what was hypothesised, oxytocin administration did not significantly 
influence smoothie intake among the AN or HC participants nor did it moderate 
subjective anxiety. However as postulated, oxytocin administration significantly 
reduced salivary cortisol and reduced the anomalies in AB towards food images in 
people with AN. Additionally, correlational analysis revealed an association between 
oxytocin-induced reduction in salivary cortisol and attentional avoidance of food 
images before the smoothie challenge.  
 
The current findings revealed that relative to the HC group, the AN participants had 
significantly higher salivary cortisol, and intranasal oxytocin reduced salivary cortisol 
levels across time points in the AN group only. This supports findings from a recent 
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6-week pilot trial that reported reductions in salivary cortisol levels and anticipatory 
cortisol response to an afternoon snack among inpatients with AN following 
repeated twice-daily administration of 18IU of intranasal oxytocin (Russell et al., 
2013). This is also consistent with findings from a recent meta-analysis, which found 
that intranasal oxytocin reduced the cortisol response to stressful stimuli among 
clinical populations, with conditions characterised by dysregulation of the HPA axis 
(Cardoso et al., 2014). These findings suggest that oxytocin is able to moderate both 
acute and chronic stress response among clinical populations. Previous work has 
suggested that increased availability of another hypothalamic neuropeptide, 
vasopressin, plays an important role in dysregulated and elevated neurobiological 
stress response in AN (Connan et al., 2003). Oxytocin may moderate this system by 
reducing vasopressin availability, thus, reducing elevated stress response (Heinrichs 
and Domes, 2008; Heinrichs et al., 2009). Another possibility is that the 
dysregulation of the HPA axis and associated elevated stress response are due to a 
failure in the stress-induced up-regulation of endogenous oxytocin (Zheng et al., 
2010). Intranasal oxytocin may then moderate the stress response by regulating HPA 
axis activity (Neumann and Slattery, 2016). Although the exact mechanism of the 
effects of oxytocin on neurobiological stress is still not clear and need further 
exploration, these findings raise the possibility that oxytocin might have a role as a 
neuroenhancer that facilitates extinction learning as has been proposed based on 
recent findings from animal studies (Eckstein et al., 2015; Hofmann et al., 2015; 
Stockhorst and Antov, 2016).  
 
 19 
The current study also found that relative to HCs, AN participants had anomalies in 
AB towards food images, showing greater avoidance of food images before the 
smoothie challenge and greater bias towards food images after the smoothie 
challenge, although this failed to reach significance. Oxytocin administration altered 
these anomalies significantly reducing bias towards food images after the smoothie 
challenge in the AN group. The moderation of the anomalies in AB toward food are 
in keeping with previous work exploring the effects of intranasal oxytocin on 
attentional processing in AN (Kim et al., 2014a; Kim et al., 2014b).  The authors 
reported that intranasal oxytocin significantly reduced bias towards illness-related 
stimuli, including images of food, eating, fat body shape, and disgusted faces in AN 
(Kim et al., 2014a; Kim et al., 2014b).  These findings suggest that intranasal oxytocin 
can alter automated attentional processing of illness-related stimuli, which would 
otherwise be difficult to target through talking therapies. Additionally, it has recently 
been suggested that oxytocin may be a useful supplement to treatment as usual in 
eating disorders (Maguire et al., 2013; Treasure et al., 2015). 
 
The current study also attempted to explore the mechanism of the effects of 
oxytocin on attentional processes. The findings revealed a significant inverse 
correlation between oxytocin-induced reduction in AB away from food images and 
oxytocin-induced reduction in salivary cortisol before the smoothie challenge. These 
findings suggest that as intranasal oxytocin reduced salivary cortisol, it also reduced 
attentional avoidance of food images before the smoothie challenge. This is in 
accordance with findings from animal studies demonstrating that central oxytocin 
release reduces neurobiological stress and stress-related behaviours, such as hiding 
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during an open field test and periods of immobility during forced swimming test 
(Chaviaras et al., 2010; Zheng et al., 2010). These findings are also supported by a 
previous functional neuroimaging study, which found that intranasal oxytocin 
normalises anxiety-induced amygdala hyper-reactivity to threatening, illness related 
stimuli in generalised social anxiety disorder (Labuschagne et al., 2010). 
Furthermore, among people with fragile X syndrome, characterised by autism-like 
difficulties in social processing, intranasal oxytocin has been shown to reduce 
salivary cortisol and improve eye gaze during social interaction (Hall et al., 2012). 
However, it is of note that in the current study we were not able to find a significant 
correlation between oxytocin-induced changes in AB towards food images and 
salivary cortisol or self-reported anxiety, which may have been due to timing of the 
final saliva sample collected after the smoothie challenge (Hellhammer et al., 2009). 
Therefore, further research using functional neuroimaging techniques are needed to 
further examine the mechanism through which intranasal oxytocin alters attentional 
processes in AN. 
 
Oxytocin administration did not significantly alter smoothie intake in either the AN 
or HC group in the current study. Previous findings from studies investigating the 
effects of a single dose of intranasal oxytocin on eating behaviour in humans are 
variable (Olszewski et al., 2016). One study reported that intranasal oxytocin 
reduced food intake during a buffet test meal in healthy men following an overnight 
fast (Lawson et al., 2015). On the other hand, another study failed to find significant 
oxytocin-induced reduction in food intake during a buffet breakfast following an 
overnight fast (Ott et al., 2013). Instead the authors reported that intranasal 
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oxytocin reduced hedonic snacking two hours after the test meal (Ott et al., 2013). 
Interestingly, the buffet test meal in the Lawson et al. (2015) had more variety and 
contained more options than that in the Ott et al. (2013) study. Variety has been 
shown to be an important factor increasing hedonic value of food and intake during 
buffet test meals (Brondel et al., 2009; Hetherington et al., 2006). The current study 
conducted in the afternoon and participants had not consumed any food for at least 
three hours by the time they were introduced to the test meal consisting of a single 
fruit smoothie. It is probable that clinical status, hedonic hunger, and the context of 
the test meal may influence the effect of oxytocin on eating.   
 
Considering the important role that chronic neurobiological stress and information 
processing biases play in the maintenance of disordered eating, it was perhaps 
surprising that oxytocin-induced reduction in salivary cortisol and in automated AB 
towards food images did not translate into greater intake during the smoothie 
challenge and less anxiety throughout the session. It is possible that a test meal 
disguised as a “taste test” might be a more sensitive outcome as it would allow a 
covert assessment of intake of various different types of food and micronutrients. 
Additionally, using ecologically valid assessments such as 24-hour food diaries could 
help to further investigate the effects of intranasal oxytocin on food intake under 
naturalistic settings. Indeed, a recent proof of concept study by Kim et al. (2015), 
which used 24-hour food diaries, found that a single dose of intranasal oxytocin 
reduced caloric intake among people with bulimia nervosa. The authors did not find 
any increase in caloric intake among people with AN (Kim et al., 2015). However, it is 
of not that the AN participants in the Kim et al. (2015) study were all inpatients 
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undergoing treatment. Thus, further investigation of the effects of intranasal 
oxytocin on food intake among people with AN under naturalistic conditions would 
be necessary before recommendations regarding its potential as an add-on 
treatment can be made. 
 
Finally, the demographic data, including questionnaire responses, age, and BMI, in 
the current study was skewed. However this is not unusual with questionnaire and 
other measures that contain natural boundaries, below or above which the data 
can’t reach (Diez et al., 2015). For instance, the age data is skewed because in the 
current study we only recruited adults over the age of 18. Therefore, we have a 
natural boundary at 18 years and for this reason the data has a right skew. 
Similarly, a person’s BMI cannot be below a certain point, but there is no clear 
upper limit, meaning that the data has a natural right skew. 
 
Limitations 
One of the limitations of the current study was the smoothie challenge used in the 
current study, which differed from test meal challenges employed in other studies 
(Khalsa et al., 2015; Lawson et al., 2013a; Steinglass et al., 2014). The fruit smoothies 
are marketed as healthy and previous studies found them to be acceptable for the 
AN participants (Cardi et al., 2013). However, the smoothie challenge consisted of a 
single 250ml smoothie, which in some cases led to ceiling effects. Future studies may 
benefit from employing test meals that include both high and low calorie options. 
Additionally, since the smoothie options varied slightly in their calorie content 
(range: 126-140 Kcal), we were not able to validly analyse the data in calories 
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consumed during the challenge. Future studies using similar smoothie challenge 
paradigm may benefit from matching the smoothies offered for caloric content. 
 
Additionally, the type of visual probe task used to measure attention in the current 
study precluded the measurement of timing related changes in AB. Future research 
may benefit from exploring the effects of oxytocin on early and late attentional 
processes in AN using eye tracking and functional neuroimaging techniques such as 
EEG and MEG. Furthermore, the neutral images consisted of pictures of furniture 
and rooms, which were not similarly standardised as the food images. Although, 
prior to the study, effort was taken to ensure the images were as visually appealing 
as the food images, in terms of colour and contrast, this may have added noise to 
the data. It has also been recently proposed that standardised images should be 
used in order to improve comparability of studies and increase replicability and 
reproducibility of findings (Blechert et al., 2014). 
 
Further, the sessions were very close together. Although, this was unlikely to 
influence the results of the rapid behavioural task and biological measures, it would 
be beneficial for the current findings to be replicated with a larger study using a 
longer period between the sessions.  
 
Finally, salivary cortisol measures were taken only at three different time points. It is 
possible that we did not find a correlation between oxytocin-induced changes in 
salivary cortisol and AB after the smoothie challenge because the saliva sample was 
taken too soon after the challenge. It has been suggested that relative to 
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psychological responses, there can be considerable lag in the cortisol response to 
stressful, anxiety-provoking stimuli (Hellhammer et al., 2009). Future research would 
benefits from building on these findings and further investigating the timeline of the 
effects of oxytocin on stress in AN and how these effects may correlate with 
psychological responses.  
 
Conclusions 
The current study examined the effects of a single dose of intranasal oxytocin on a 
smoothie challenge, salivary cortisol, and AB towards food images in AN. The 
findings revealed that intranasal oxytocin did not significantly increase smoothie 
intake during the smoothie challenge, but did significantly reduce salivary cortisol in 
the AN group. Oxytocin did influence food-related attentional bias, which correlated 
with oxytocin-induced reduction in salivary cortisol in the AN group. Taken together, 
these findings suggest that the oxytocin may be helpful in altering automatic 
information processing biases and inhibiting the hyperactivation of the HPA axis and 
may enhance the therapeutic benefits of food exposure paradigms in anorexia 
nervosa. Still, it will be necessary to further examine the exact mechanism through 
which oxytocin exerts its effects in AN as well as the effects of chronic administration 
on illness related processes and eating behaviours over the long term, before any 
recommendation can be made regarding whether intranasal oxytocin could be 
introduced into treatment of AN.  
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Table 1. Clinical and demographic sample characteristics 
 
 
AN (N = 30) HC (N = 29) AN vs HC 
Median Q1 Q3 Median Q1 Q3 Χ2 statistic, p 
value 
Cramer
’s ϕ 
BMI 
16.13 14.56 18.14 22.21 20.78 25.51 
Χ2 = 35.55, p< 
0.001  0.78 
Age 
24.50 22.00 28.25 25.00 23.00 27.50 
Χ2 = 0.02, p= 
0.875 0.02 
EDEQ total 
4.13 3.00 5.13 0.59 0.34 1.00 
Χ2 = 35.27, p< 
0.001 0.77 
EDEQ 
restraint 3.70 2.60 5.05 0.60 0.00 1.70 
Χ2 = 20.79, p< 
0.001 0.59 
EDEQ 
weight 
concern 4.20 2.70 5.65 0.60 0.30 1.40 
Χ2 = 31.38, p< 
0.001 0.73 
EDEQ 
shape 
concern 4.86 3.56 5.91 0.75 0.38 1.38 
Χ2 = 41.67, p< 
0.001 0.84 
EDEQ 
eating 
concern 4.10 2.90 4.80 0.20 0.00 0.40 
Χ2 = 41.67, p< 
0.001 0.84 
DASS Total 
63.00 40.00 86.00 4.00 1.00 10.00 
Χ2 = 37.49, p< 
0.001 0.80 
DASS 
Depression 21.00 13.50 32.00 0.00 0.00 2.00 
Χ2 = 26.61, p< 
0.001 0.67 
DASS 
Anxiety 12.00 6.00 21.00 0.00 0.00 2.00 
Χ2 = 29.07, p< 
0.001 0.70 
DASS 
Stress 25.00 17.50 31.00 2.00 0.00 7.00 
Χ2 = 37.49, p< 
0.001 0.80 
AN = anorexia nervosa, HC = healthy comparison, BMI = Body mass index, EDEQ = 
Eating Disorder Examination Questionnaire, DASS = Depression, Anxiety, and Stress 
Scale 
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Table 2. Smoothie intake in millilitres (ml) in the AN and HC groups in the oxytocin 
and placebo conditions.  
 
Drug 
AN (N = 
30) 
Mean (SD) 
HC (N = 29) 
Mean (SD) Χ2 statistic, p value 
Oxytocin 113.10 
(102.94) 
224.24 
(47.58) 
Drug: Χ2 = Χ2 = 1.39, p = 0.239 
Group: Χ2 = Χ2 = 131.66, p <0.001 
Drug x Group: Χ2 = Χ2 < 0.01, p = 0.975 
 
Placebo 99.07 
(102.16) 
237.52 
(30.29) 
AN = anorexia nervosa, HC = healthy comparison 
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Table 3. AB towards food images before and after the test meal in the AN and HC 
groups.  
ITI Time Drug 
AN (N = 
30) 
Mean (SD) 
HC (N = 29) 
Mean (SD) Χ2 statistic, p value 
500ms Before 
test 
meal 
Oxytocin -2.66 
(33.57) 
2.52 (36.79) Drug: Χ2 = 1.41, p = 0.234 
Time: Χ2 = 0.08, p = 0.780 
Group: Χ2 = 3.47, p = 0.063 
Drug x Time: Χ2 = 0.09, p = 0.764 
Drug x Group: Χ2 = 1.06, p = 0.302 
Time x Group: Χ2 = 2.81, p = 0.093 
Drug x Time x Group: Χ2 = 6.49, 0.011 
 
Placebo -13.69 
(29.27) 
13.86 (42.70) 
After 
test 
meal 
Oxytocin -13.64 
(38.78) 
0.41 (43.66) 
Placebo 10.64 
(34.42) 
-2.99 (42.55) 
1250ms Before 
test 
meal 
Oxytocin -5.06 
(30.85) 
8.66 (43.47) Drug: Χ2 = 0.41, p = 0.524 
Time: Χ2 = 1.97, p = 0.160 
Group: Χ2 = 0.01, 0.925 
Drug x Time: Χ2 = 0.03, p = 0.863 
Drug x Group: Χ2 = 1.47, p = 0.226 
Time x Group: Χ2 = 0.18, p = 0.669 
Drug x Time x Group: Χ2 = 0.29, p = 0.591 
 
Placebo 2.64 
(34.08) 
-4.53 (35.44) 
After 
test 
meal 
Oxytocin -6.78 
(48.86) 
-5.24 (67.38) 
Placebo -8.13 
(41.65) 
-13.95 
(44.29) 
AN = anorexia nervosa, HC = healthy comparison, AB = Attentional bias, ITI = inter-
trial interval 
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Table 4. Salivary cortisol at each time point in the AN and HC groups 
Time Drug AN (N = 
30) 
Mean (SD) 
HC (N = 
29) 
Mean (SD) 
Χ2 statistic, p value 
Baseline Oxytocin 5.35 (5.66) 3.71 (3.68) Drug: Χ2 = 0.37, p = 0.542 
Time: Χ2 = 6.91, p = 0.032 
Group: Χ2 = 179.21, p < 0.001 
Drug x Time: Χ2 = 1.46, p = 0.482 
Drug x Group: Χ2 = 7.22, p = 0.007 
Time x Group: Χ2 = 4.33, p = 0.115 
Drug x Time x Group: Χ2 = 1.38, p = 
0.502  
Placebo 5.35 (3.31) 3.18 (2.67) 
Before 
test 
meal 
Oxytocin 4.81 (3.35) 2.57 (2.10) 
Placebo 5.54 (4.04) 2.24 (1.75) 
After 
test 
meal 
Oxytocin 4.69 (3.14) 2.59 (1.92) 
Placebo 5.93 (4.48) 2.09 (1.57) 
AN = anorexia nervosa, HC = healthy comparison 
